164 related articles for article (PubMed ID: 22871497)
21. Neoadjuvant chemotherapy increases rates of breast-conserving surgery in early operable breast cancer.
Man VC; Cheung PS
Hong Kong Med J; 2017 Jun; 23(3):251-7. PubMed ID: 28484080
[TBL] [Abstract][Full Text] [Related]
22. Radioguided occult lesion localization (ROLL) for non-palpable breast cancer: a comparison between day-before and same-day protocols.
Aydogan F; Ozben V; Celik V; Uras C; Tahan G; Gazioglu E; Cengiz A; Ferahman M; Cercel A; Yilmaz MH; Halac M; Unal H
Breast; 2010 Jun; 19(3):226-30. PubMed ID: 20163961
[TBL] [Abstract][Full Text] [Related]
23. Response of malignant breast tumours to neoadjuvant chemotherapy evaluated with Tc-99m MIBI.
Listewnik MH; Birkenfeld B; Foszczyńska-Kłoda M; Listewnik MJ; Piwowarska-Bilska H; Zorga P
Ann Acad Med Stetin; 2011; 57(1):73-8. PubMed ID: 22593995
[TBL] [Abstract][Full Text] [Related]
24. Early response to neo-adjuvant chemotherapy in carcinoma of the breast predicts both successful breast-conserving surgery and decreased risk of ipsilateral breast tumor recurrence.
Ishitobi M; Komoike Y; Motomura K; Koyama H; Inaji H
Breast J; 2010; 16(1):9-13. PubMed ID: 19929889
[TBL] [Abstract][Full Text] [Related]
25. Radioguided occult lesion localisation versus wire-guided lumpectomy in the treatment of non-palpable breast lesions.
Takács T; Paszt A; Simonka Z; Abrahám S; Borda B; Ottlakán A; Ormándi K; Lázár M; Vörös A; Kahán Z; Lazar G
Pathol Oncol Res; 2013 Apr; 19(2):267-73. PubMed ID: 23065470
[TBL] [Abstract][Full Text] [Related]
26. Randomized controlled clinical trial comparing radioguided occult lesion localization with wire-guided lesion localization to evaluate their efficacy and accuracy in the localization of nonpalpable breast lesions.
Duarte C; Bastidas F; de los Reyes A; Martínez MC; Hurtado G; Gómez MC; Sánchez R; Manrique J
Surgery; 2016 Apr; 159(4):1140-5. PubMed ID: 26549819
[TBL] [Abstract][Full Text] [Related]
27. Residual specimen cellularity after neoadjuvant chemotherapy for breast cancer.
Peintinger F; Kuerer HM; McGuire SE; Bassett R; Pusztai L; Symmans WF
Br J Surg; 2008 Apr; 95(4):433-7. PubMed ID: 18161887
[TBL] [Abstract][Full Text] [Related]
28. Intraoperative ultrasound in conservative surgery for non-palpable breast cancer after neoadjuvant chemotherapy.
Ramos M; Díez JC; Ramos T; Ruano R; Sancho M; González-Orús JM
Int J Surg; 2014; 12(6):572-7. PubMed ID: 24735893
[TBL] [Abstract][Full Text] [Related]
29. [Breast-conserving surgery for breast cancer: still much to be gained].
Krekel NM; Haloua MH; Muller S; Bergers E; Rietveld DH; Meijers S; van den Tol MP
Ned Tijdschr Geneeskd; 2012; 156(29):A3573. PubMed ID: 22831490
[TBL] [Abstract][Full Text] [Related]
30. A nomogram for predicting locoregional recurrence in primary breast cancer patients who received breast-conserving surgery after neoadjuvant chemotherapy.
Matsuda N; Hayashi N; Ohde S; Yagata H; Kajiura Y; Yoshida A; Suzuki K; Nakamura S; Tsunoda H; Yamauchi H
J Surg Oncol; 2014 Jun; 109(8):764-9. PubMed ID: 24647874
[TBL] [Abstract][Full Text] [Related]
31. Editorial on "Radioguided occult lesion localization (ROLL) versus wire-guided lumpectomy for non-palpable breast lesions: a randomized prospective evaluation" by Medina-Franco H, et al.
Bland KI
J Surg Oncol; 2008 Feb; 97(2):101-2. PubMed ID: 18181140
[No Abstract] [Full Text] [Related]
32. Prognostic value of (99m)Tc-sestamibi washout in predicting response of locally advanced breast cancer to neoadjuvant chemotherapy.
Sciuto R; Pasqualoni R; Bergomi S; Petrilli G; Vici P; Belli F; Botti C; Mottolese M; Maini CL
J Nucl Med; 2002 Jun; 43(6):745-51. PubMed ID: 12050317
[TBL] [Abstract][Full Text] [Related]
33. [SPECT-CT: a new tool for localisation of sentinel lymph nodes in breast cancer patients].
Mucientes Rasilla J; Farge Balbín L; Cardona Arboniés J; Moreno Elola-Olaso A; Delgado-Bolton R; Izarduy Pereyra L; Rodríguez Rey C; Lapeña Gutiérrez L; González Maté A; Román Santamaría JM; Carreras Delgado JL
Rev Esp Med Nucl; 2008; 27(3):183-90. PubMed ID: 18570860
[TBL] [Abstract][Full Text] [Related]
34. Neoadjuvant interstitial high-dose-rate (HDR) brachytherapy combined with systemic chemotherapy in patients with breast cancer.
Roddiger SJ; Kolotas C; Filipowicz I; Kurek R; Kuner RP; Martin T; Baltas D; Rogge B; Kontova M; Hoffmann G; Pollow B; Zamboglou N
Strahlenther Onkol; 2006 Jan; 182(1):22-9. PubMed ID: 16404517
[TBL] [Abstract][Full Text] [Related]
35. Time to go wireless? A 15-year single institution experience of radioisotope occult lesion localisation (ROLL) for impalpable breast lesions.
Hawkins SC; Brown I; King P; El-Gammal M; Stepp K; Widdison S; Barta M; Jackson N; Drew P; English R; Ahmad S
Eur J Surg Oncol; 2017 Jan; 43(1):62-67. PubMed ID: 27667335
[TBL] [Abstract][Full Text] [Related]
36. Simultaneous use of an (125)I-seed to guide tumour excision and (99m)Tc-nanocolloid for sentinel node biopsy in non-palpable breast-conserving surgery.
Pouw B; van der Ploeg IM; Muller SH; Valdés Olmos RA; Janssen-Pinkse LK; Oldenburg HS; Vrancken Peeters MT
Eur J Surg Oncol; 2015 Jan; 41(1):71-8. PubMed ID: 25458078
[TBL] [Abstract][Full Text] [Related]
37. Tumor clearance of technetium 99m-sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer.
Ciarmiello A; Del Vecchio S; Silvestro P; Potena MI; Carriero MV; Thomas R; Botti G; D'Aiuto G; Salvatore M
J Clin Oncol; 1998 May; 16(5):1677-83. PubMed ID: 9586878
[TBL] [Abstract][Full Text] [Related]
38. Nonpalpable breast lesions: preoperative radiological guidance in radioguided occult lesion localisation (ROLL).
Belloni E; Canevari C; Panizza P; Marassi A; Rodighiero M; Tacchini S; Zuber V; Sassi I; Gianolli L; Fazio F; Del Maschio A
Radiol Med; 2011 Jun; 116(4):564-74. PubMed ID: 21431301
[TBL] [Abstract][Full Text] [Related]
39. Surgery following neoadjuvant chemotherapy for HER2-positive locally advanced breast cancer. Time to reconsider the standard attitude.
Debled M; MacGrogan G; Breton-Callu C; Ferron S; Hurtevent G; Fournier M; Bourdarias L; Bonnefoi H; Mauriac L; Tunon de Lara C
Eur J Cancer; 2015 Apr; 51(6):697-704. PubMed ID: 25704790
[TBL] [Abstract][Full Text] [Related]
40. [Neoadjuvant systemic therapy in patients with operable primary breast cancer: more benefits than breast-conserving therapy].
Straver ME; van Adrichem JC; Rutgers EJ; Rodenhuis S; Linn SC; Loo CE; Gilhuijs KG; Oldenburg HS; Wesseling J; Russell NS; Antonini N; Vrancken Peeters MT
Ned Tijdschr Geneeskd; 2008 Nov; 152(46):2519-25. PubMed ID: 19055260
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
